



Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd. (the “Issuer”)

USD 300 Million Zero Coupon Convertible Bonds due 2026

(ISIN: XS2352395748) and

RMB 1,916 Million USD Settled Zero Coupon Convertible Bonds due 2026

(ISIN: XS2353011724)

(together, the “Bonds”)

Notice to the Trustee, the Agents and the Bondholders

Unless otherwise defined herein, capitalized terms in this notice shall have the same meanings as those defined in the terms and conditions of the Bonds (the “**Conditions**”), and the circular of the Issuer to be dated and published on or around September 7, 2022 on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.pharmaron.com).

Closure of Register of Shareholders

In accordance with the respective Trust Deed of the Bonds executed on June 18, 2021 and pursuant to the Conditions, the Issuer hereby wishes to inform you that the Issuer’s register of Shareholders (the “**Register of Shareholders**”) will be closed from Tuesday, September 20, 2022 to Friday, September 23, 2022 (both days inclusive) for determining the H Shareholders entitled to attend and vote at the EGM, and re-opened on Monday, September 26, 2022.

Conversion Restriction Period

Pursuant clause 5.1.1 of the Conditions, the Issuer also wishes to inform you that the Conversion Right may not be exercised for any Bonds during the following periods:

- (a) between Thursday, September 8, 2022 and Friday, September 23, 2022 (both days inclusive), i.e., commencing on the date falling 15 days prior to the EGM and ending on the date of that EGM; and
- (b) during the periods of Closure above, i.e., commencing on such date and for such period as determined by applicable law from time to time that the Issuer is required to close its register.

(the “**Conversion Restriction Period**”)

For the purpose of this notice, “working day” means a day other than a Saturday, Sunday or a public holiday on which commercial banks and foreign exchange markets are open for business in London.

In the event of any amendments to the Conversion Restriction Period, the Company shall notify you in writing promptly upon the confirmation of any such amendments.

Any Bondholder who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

For and on behalf of
Pharmaron Beijing Co., Ltd.
(康龙化成(北京)新药技术股份有限公司)



Authorised Signatory
Name: LI Shing Chung Gilbert
Title: Chief Financial Officer
8th Floor, Block 1
6 Tai-He Road
Beijing Economic Technological Development Area
Beijing, China